This item is under embargo and not available online per the author's request. For access information, please visit http://libanswers.wustl.edu/faq/5640.

Date of Award

Fall 12-20-2017

Author's School

School of Engineering & Applied Science

Author's Department

Biomedical Engineering

Degree Name

Master of Science (MS)

Degree Type

Thesis

Abstract

Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided brain tumor resection.

Language

English (en)

Chair

Samuel Achilefu

Committee Members

Monica Shokeen, Quing Zhu

Comments

Permanent URL: https://doi.org/10.7936/K7319V99

Available for download on Friday, January 17, 2020

Share

COinS